Taiho Pharma
Tokyo, Japan· Est.
Japanese oncology-focused pharmaceutical company with expertise in oral anticancer agents and global commercialization.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Japanese oncology-focused pharmaceutical company with expertise in oral anticancer agents and global commercialization.
OncologyImmunologyUrology
Technology Platform
Specialized in small molecule drug discovery with expertise in oral anticancer agents, particularly nucleoside analogs and combination formulations. Expanding into biologics and cancer vaccine development.
Opportunities
Expansion of LONSURF into new indications and geographic markets, advancement of immuno-oncology pipeline including TIGIT/PD-1 combinations, and development of novel cancer vaccine platforms through collaborations.
Risk Factors
Intense competition in oral oncology market, pipeline dependency on successful Phase 3 readouts, and challenges in differentiating newer mechanisms in crowded immuno-oncology space.
Competitive Landscape
Competes with global oncology leaders like Roche, Merck, and Bristol Myers Squibb, but differentiates through specialized oral formulation expertise and niche focus within the larger Otsuka Group ecosystem.